Lexeo Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | $-100.0M | $-98.3M | $-66.4M | $-59.3M |
| Depreciation & Amortization | $268.0K | $304.0K | $271.0K | $120.0K |
| Depreciation | — | — | — | — |
| Amortization | — | — | — | — |
| Stock-Based Compensation | $12.1M | $12.5M | $3.0M | $1.8M |
| Net Cash from Operating Activities | $-98.6M | $-81.2M | $-59.5M | $-54.6M |
| Investing Activities | ||||
| Capital Expenditures | $397.0K | $481.0K | $115.0K | $672.0K |
| Business Acquisitions | — | — | — | — |
| Net Cash from Investing Activities | $-90.3M | $-94.1M | $-165.0K | $-901.0K |
| Financing Activities | ||||
| Dividends Paid | — | — | — | — |
| Stock Repurchases | — | — | — | — |
| Net Cash from Financing Activities | $216.8M | $88.8M | $103.8M | $189.0K |
| Net Change in Cash | $28.0M | $-86.5M | $44.1M | $-55.3M |
| Free Cash Flow | $-99.0M | $-81.6M | $-59.6M | $-55.2M |